Loading...
StocksRunner logo
 
 
AnaptysBio
18.05
-1.47%
 
ANAB AnaptysBio
Last Price
Change
18.05
 
-1.47%
 
 
 

 
Sentiment
 
 

21.11

21.8

26.66

20.8

 
 
1m
3m
6m
1y
 

Summary

  Login to display AnaptysBio (ANAB) recommendation from the last 90 days from financial news and social media.
 

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

 
 

Risk Level

 
StocksRunner
 

AnaptysBio (ANAB) has Moderate Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

2.00
 

StocksRunner

 Below analyst estimate

 
 

Rating

×
 

Rating

3.29
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

NA
 
 

Activity

×
 

Activity

2.00
 
 

Future

×
 

Future

4.50
 

StocksRunner

 Outperform the market

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
55%
57%
NA
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is bullish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
55%
45%
Positive
Negative
6 out of 11
events present
5 out of 11
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Upgrade
2 Weeks Ago
19.93
+4.18%
 
Buy Rating
3 Weeks Ago
19.45
-6.29%
 
Weak Earnings
3 Weeks Ago
20.92
-2.61%
 
Top Headlines

jp morgan upgrades anaptysbio (anab). fintel reports that on may 22 2023 jp morgan upgraded their outlook for anaptysbio (nasdaq:anab) from underweight to neutral .

Mon May 22, 2023

Rating
Rating

anaptysbio upgraded to neutral at jp morgan on clinical execution.

Mon May 22, 2023

Rating

: anaptysbio upgraded to neutral from underweight at j.p. morgan. this is a real-time headline. these are breaking news delivered the minute it happens delivered ticker-tape style. visit www.marketwatch.com or the e page for more information about this br

Mon May 22, 2023

Rating
Rating

anaptysbio initiated outperform at td cowen on anti-inflammatory agents.

Thu May 18, 2023

Potential

guggenheim maintains anaptysbio (anab) buy recommendation. fintel reports that on may 12 2023 guggenheim maintained coverage of anaptysbio (nasdaq:anab) with a buy recommendation.

Fri May 12, 2023

Rating

anaptysbio inc. (anab) reports q1 loss misses revenue estimates. anaptysbio inc. (anab) came out with a quarterly loss of $1.58 per share versus the zacks consensus estimate of a loss of $1.04. this compares to loss of $1.31 per share

Thu May 11, 2023

Earnings

anaptysbio gaap eps of -$1.58 misses by $0.53 revenue of $1.4m misses by $1.48m.

Thu May 11, 2023

Earnings

wall street analysts predict a 45.12% upside in anaptysbio inc. (anab): heres what you should know. anaptysbio inc. (anab) closed the last trading session at $21.50 gaining 0.9% over the past four weeks but there could be plenty of up

Thu May 4, 2023

Potential

jp morgan maintains anaptysbio (anab) underweight recommendation. fintel reports that on april 12 2023 jp morgan maintained coverage of anaptysbio (nasdaq:anab) with

Wed Apr 12, 2023

Rating

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily ANAB alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

ANAB AnaptysBio

Last Price
18.05
Change
-1.47%
 

Summary

  Login to display AnaptysBio (ANAB) recommendation from the last 90 days from financial news and social media.

 
 
21.11
21.8
26.66
20.8
 
 
1m
3m
6m
1y
 
Sentiment

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
57%
NA
100%
On Track
On Track
On Track
 
55%
45%
Positive
Negative
6 out of 11
events present
5 out of 11
events present
 

Street Opinion

Street view is bullish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

2.00
 

StocksRunner

 Below analyst estimate

 
 

Rating

×
 

Rating

3.29
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

NA
 
 

Activity

×
 

Activity

2.00
 
 

Future

×
 

Future

4.50
 

StocksRunner

 Outperform the market

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

AnaptysBio (ANAB) has Moderate Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Upgrade
2 Weeks Ago
19.93
+4.18%
 
Buy Rating
3 Weeks Ago
19.45
-6.29%
 
Weak Earnings
3 Weeks Ago
20.92
-2.61%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily ANAB Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines